Science
Since its inception in 2014, GSL has developed disruptive technologies in the biotech and related industries. GSL’s goal is to commercialize these technologies via its various subsidiaries.
To date, GSL has advanced on the following business lines:
- My Next Health’s a genomics driven digital therapeutics platform, which combines big data and genomic insights with conversational AI and tracking tools.
- Agentix Biosciences, a pharmaceutical and nutraceutical company.
- Nectar Health Sciences, a chemistry based technology to isolate cannabinoids at high levels of purity.
- Kalmex Inc., a membrane based technology which produces full spectrum cannabinoid extracts at large industrial scale.
Science
Technology
Innovation
Since its inception in 2014, GSL has developed disruptive technologies in the biotech and related industries. GSL’s goal is to commercialize these technologies via its various subsidiaries.
To date, GSL has advanced on the following business lines:
- My Next Health’s a genomics driven digital therapeutics platform, which combines big data and genomic insights with conversational AI and tracking tools.
- Agentix Biosciences, a pharmaceutical and nutraceutical company.
- Nectar Health Sciences, a chemistry based technology to isolate cannabinoids at high levels of purity.
- Kalmex Inc., a membrane based technology which produces full spectrum cannabinoid extracts at large industrial scale.
RESEARCH
For several decades cannabinoids have been gaining momentum, amongst the medical community, in becoming an accepted form of therapeutic benefit for a wide variety of diseases. Our scientists have compiled and prioritized many of the most relevant studies, enabling us to sort and prioritize our development objectives to better service our markets.
RESEARCH
For several decades cannabinoids have been gaining momentum, amongst the medical community, in becoming an accepted form of therapeutic benefit for a wide variety of diseases. Our scientists have compiled and prioritized many of the most relevant studies, enabling us to sort and prioritize our development objectives to better service our markets.
PATIENT FOCUSED
Patients with different diseases need different formulations of cannabinoids, in different concentrations. Green Sky Labs focuses on the development of custom formulations to address some common widespread conditions as well as some of the more specific medical indications.
PATIENT FOCUSED
Patients with different diseases need different formulations of cannabinoids, in different concentrations. Green Sky Labs focuses on the development of custom formulations to address some common widespread conditions as well as some of the more specific medical indications.